JCB, Volume 16, Number 2, 2010 Editorial Vol.16 No. 2 (2010) Case studies in innovation: What enables outstanding achievements? Yali Friedman In fostering innovation, be it in biotechnology or in another field, a persistent challenge is to understand the factors enabling success. It is not sufficient to simply be Abstract Download PDF Articles Vol.16 No. 2 (2010) Biotechnology marketing: Insider and outsider views Päivi Eriksson This paper explores biotechnology marketing as defined, performed and organised in small biotechnology companies. Prior research has argued on the one hand that marketi Abstract Download PDF Articles Vol.16 No. 2 (2010) The current M&A environment and its strategic implications for emerging biotherapeutics companies Mohan Sowlay The age of the blockbuster drug may have come and gone. With dwindling pipelines and increasing generic competition, pharmaceutical companies continue to create efficie Abstract Download PDF Articles Vol.16 No. 2 (2010) Practical approaches to early stage life sciences technology valuations Stephen Mayhew With fierce competition in the market for late stage life sciences assets, pharmaceutical companies seeking partnering strategies to bolster pipelines and drive long-te Abstract Download PDF Articles Vol.16 No. 2 (2010) Commercializing synthetic biology: Socio-ethical concerns and challenges under intellectual property regime Trichi Saukshmya Synthetic biology also termed as ‘genomic alchemy’ represents a powerful area of science that is based on the convergence of biological sciences with syste Abstract Download PDF Articles Vol.16 No. 2 (2010) From carbon to carbohydrates: Corporate strategies for biopolymer technology development Avrath Chadha Since a few years the worldwide demand for biopolymers is increasing significantly. Many firms are trying to avoid the price spiral of fossil fuels by utilising renewab Abstract Download PDF Articles Vol.16 No. 2 (2010) Biotechnology in the capital region of Europe Jan Wauters It has never been as challenging in biotechnology as today. Convergence is the key word, forcing alliances between pharmaceuticals and biology, and new economic opportu Abstract Download PDF Legal and Regulatory Updates Vol.16 No. 2 (2010) Legal and regulatory update Gerry Kamstra   Abstract Download PDF Conference Report Vol.16 No. 2 (2010) Funding the dream at the Mid-Atlantic Biotech Conference Harley King   Abstract Download PDF Book Reviews Vol.16 No. 2 (2010) Book Review: Getting to Plan B: Breaking through to a better business model Arlen D Meyers Getting to Plan B: Breaking through to a better business modelJohn Mullins and Randy KomisarHarvard Business School Press, Boston, MA, 2009, hardback, 249pp.,ISBN: 97 Abstract Download PDF Book Reviews Vol.16 No. 2 (2010) Book Review: Driving innovation – Intellectual property strategies for a dynamic world Barry J Marenberg Driving innovation – Intellectual property strategies for a dynamic worldMichael A. GollinCambridge University Press, New York, 2008, paperback, 415pp.,ISBN: 9 Abstract Download PDF Book Reviews Vol.16 No. 2 (2010) Book Review: Intellectual property, medicine and health: Current debates Stanley P Kowalski Intellectual property, medicine and health: Current debatesJohanna GibsonAshgate, Farnham, England and Burlington, VT, USA, 2009, hardback, 223pp.,ISBN: 978-075467218 Abstract Download PDF
